Results 41 to 50 of about 5,784 (166)

Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis

Acta Neuropathologica Communications, 2019
Background Medulloblastoma (MB) is the most common malignant brain tumour in children but also rarely occur in adults. Sonic Hedgehog (SHH) driven MB is associated with aberrant activation of the SHH signalling pathway.
Yuchen Li, Qingkun Song, Bryan W. Day
doaj   +1 more source

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis

Frontiers in Oncology, 2020
In this pilot study, we describe our experience with vismodegib in the treatment of basal cell carcinoma (BCC) and evaluate the feasibility of a tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced BCC.
Maria Chiara Tronconi, Alessandra Solferino, Laura Giordano, Riccardo Borroni, Riccardo Borroni, Luca Mancini, Armando Santoro, Armando Santoro   +7 more
doaj   +1 more source

Cancer‐associated fibroblast heterogeneity across solid and haematological malignancies: Lessons from colorectal cancer and multiple myeloma

The Journal of Physiology, EarlyView.
Abstract figure legend CAF origins and plasticity give rise to distinct phenotypes with immunosuppressive functions in colorectal cancer and multiple myeloma. These distinct CAF phenotypes contribute to immunosuppressive tumour microenvironments through ECM remodelling, cytokine signalling and immune regulation.
Hui Mo, Haoyan Han, Michael O'Dwyer, Eileen Reidy, Aideen E. Ryan   +4 more
wiley   +1 more source

Advanced basal cell carcinoma treated with vismodegib

, 2020
A. 64 yowf with nodular and micronodular BCC on back. Treated with vismodegib 150mg Mon-Fri with tumor shrinkage to 23 by 7cm after a six month course and treated subsequently with a radical resection and removal of T2-L1 spinous processes.
Wong, C (via Mendeley Data), Wong, Christina   +1 more
core   +2 more sources

Long-Term Success in the Management of an Extensive Medial Canthal Basal-Cell Carcinoma with Vismodegib

Journal of Current Ophthalmology
Purpose: To present a case of an extensive basal-cell carcinoma (BCC) of the medial canthus that was successfully treated with vismodegib. The introduction of vismodegib and other Hedgehog pathway inhibitors into clinical practice has provided a new ...
Argyrios Tzamalis, Georgios Lavasidis, Ioannis Tsinopoulos, Nikolaos Ziakas   +3 more
doaj   +1 more source

Deciphering the Allosteric Effect of Antagonist Vismodegib on Smoothened Receptor Deactivation Using Metadynamics Simulation

Frontiers in Chemistry, 2019
The smoothened receptor (Smo) plays a key role in Hedgehog (Hh) signaling pathway and it has been regarded as an efficacious therapeutic target for basal cell carcinoma (BCC) and medulloblastoma (MB).
Xiaoli An, Qifeng Bai, Fang Bai, Danfeng Shi, Huanxiang Liu, Xiaojun Yao, Xiaojun Yao   +6 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma

Cancer Treatment and Research Communications
The management of periocular basal cell carcinoma (BCC) is challenging due to its proximity to the eyeball. Vismodegib, a Hedgehog pathway inhibitor, has emerged as a therapeutic option for locally advanced and metastatic BCC.
Georgios Lavasidis, Argyrios Tzamalis, Ioannis Tsinopoulos, Nikolaos Ziakas   +3 more
doaj   +1 more source

Giant morphea-form basal cell carcinoma of the umbilicus: Successful debulking with vismodegib

Rare Tumors, 2018
Basal cell carcinoma of the umbilicus is very rare. The nodular subtype is the main representative. Giant basal cell carcinomas represent around 1% of all basal cell carcinomas.
Mariana Orduz Robledo, Eve Lebas, Marie-Annick Reginster, Mahmoud Baghaie, Sabine Groves, Arjen F Nikkels   +5 more
doaj   +1 more source

Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro

, 2019
Background and ObjectiveHedgehog inhibitors such as vismodegib are targeted drugs widely used for the treatment of basal cell carcinomas; however, their use is significantly limited by frequent systemic side effects due to oral administration route.
Merete Haedersdal, Lerche, Catharina M, Hædersdal, Merete, Gael Clergeaud, Clergeaud, Gael, Uffe H. Olesen, Lerche, Catharina M., Haedersdal, Merete, Thomas L. Andresen, Olesen, Uffe H., Andresen, Thomas L., Catharina M. Lerche   +11 more
core   +1 more source